Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen Regains Nasdaq Compliance by Moving to Cap Market

NEW YORK (GenomeWeb News) – Ciphergen Biosystems today said its shares have regained compliance with the Nasdaq exchange after it allowed the company to move its shares to its Capital Market from the National Market.
To remain listed on the Capital Market Ciphergen must, among other things, have a market capitalization greater than $35 million, the company said in a Securities and Exchange Commission filing today. Ciphergen’s market cap is currently around $48 million.
As GenomeWeb News reported in July, the Nasdaq notified Ciphergen that it is subject to delisting from the National Market because its market cap had fallen below $50 million for 10 consecutive business days.
Its stock will trade on the Capital Market on Aug. 28 under the ticker symbol CIPH.
“By transferring from the Nasdaq Global Market to the Nasdaq Capital Market, Ciphergen satisfies the listing requirements” for the exchange, Ciphergen said in statement.
Ciphergen’s “continued listing on the Nasdaq Capital Market is subject to its successful completion of an application and review process,” the company said in the SEC filing.

The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.